LT5504B - Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti - Google Patents

Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti Download PDF

Info

Publication number: LT5504B
Authority: LT; Lithuania
Prior art keywords: thiadiazole; sulfonamide; sulfonamides; compound; preparation
Prior art date: 2006-08-02

Application number

LT2006066A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2006066A (en

Inventor

Daumantas Matulis

Virginija DUDUTIEN�

Jurgita MATULIEN�

Lina MI�TINAIT�

Original Assignee

Biotechnologijos Institutas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-02

Filing date

2006-08-02

Publication date

2008-06-25

2006-08-02 Application filed by Biotechnologijos Institutas filed Critical Biotechnologijos Institutas

2006-08-02 Priority to LT2006066A priority Critical patent/LT5504B/lt

2007-08-01 Priority to AT07793796T priority patent/ATE513836T1/de

2007-08-01 Priority to EP07793796A priority patent/EP2054420B1/de

2007-08-01 Priority to PCT/LT2007/000005 priority patent/WO2008016288A1/en

2008-02-25 Publication of LT2006066A publication Critical patent/LT2006066A/xx

2008-06-25 Publication of LT5504B publication Critical patent/LT5504B/lt

Links

108090000209 Carbonic anhydrases Proteins 0.000 title claims description 47
102000003846 Carbonic anhydrases Human genes 0.000 title claims description 47
239000000543 intermediate Substances 0.000 title claims description 24
239000003112 inhibitor Substances 0.000 title description 20
WBOJVJVWIHECCA-UHFFFAOYSA-N 1,3-dihydrothiadiazolo[3,4-a]benzimidazole-7-sulfonamide Chemical class C12=CC(S(=O)(=O)N)=CC=C2N=C2N1NSC2 WBOJVJVWIHECCA-UHFFFAOYSA-N 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 65
229940124530 sulfonamide Drugs 0.000 claims abstract description 61
150000003456 sulfonamides Chemical class 0.000 claims abstract description 45
238000002360 preparation method Methods 0.000 claims description 34
-1 SCH 3 Inorganic materials 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 23
230000005764 inhibitory process Effects 0.000 claims description 16
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 7
125000000565 sulfonamide group Chemical group 0.000 claims description 7
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
NERZQZFCTPWAFE-UHFFFAOYSA-N chembl394355 Chemical compound C12=CC(S(=O)(=O)N)=CC=C2N=C2N1N=S=C2Cl NERZQZFCTPWAFE-UHFFFAOYSA-N 0.000 claims description 5
VEINOLHERXPMLU-UHFFFAOYSA-N 1,3-dihydrothiadiazolo[3,4-a]benzimidazole Chemical compound C1=CC=C2N3NSCC3=NC2=C1 VEINOLHERXPMLU-UHFFFAOYSA-N 0.000 claims description 4
DFEZVLLEDWNYKQ-UHFFFAOYSA-N 3-methylsulfanyl-1,3-dihydrothiadiazolo[3,4-a]benzimidazole Chemical compound C1=CC=C2N3NSC(SC)C3=NC2=C1 DFEZVLLEDWNYKQ-UHFFFAOYSA-N 0.000 claims description 4
ZPOMYCFBGSDKIR-UHFFFAOYSA-N 3-methylsulfonyl-1,3-dihydrothiadiazolo[3,4-a]benzimidazole Chemical compound C1=CC=C2N3NSC(S(=O)(=O)C)C3=NC2=C1 ZPOMYCFBGSDKIR-UHFFFAOYSA-N 0.000 claims description 4
HXQVORISDJEIEN-UHFFFAOYSA-N 6-bromo-3-chloro-1,3-dihydrothiadiazolo[3,4-a]benzimidazole Chemical compound BrC1=CC=C2N3NSC(Cl)C3=NC2=C1 HXQVORISDJEIEN-UHFFFAOYSA-N 0.000 claims description 3
XOCWXPYJIBWYEZ-UHFFFAOYSA-N chembl234506 Chemical compound C1=C(S(N)(=O)=O)C=C2N3N=S=C(S(=O)(=O)C)C3=NC2=C1 XOCWXPYJIBWYEZ-UHFFFAOYSA-N 0.000 claims description 3
WEYTWMDKRFTYJN-UHFFFAOYSA-N 1,3-dihydrothiadiazolo[3,4-a]benzimidazole-3-sulfonamide Chemical class C1=CC=C2N3NSC(S(=O)(=O)N)C3=NC2=C1 WEYTWMDKRFTYJN-UHFFFAOYSA-N 0.000 claims description 2
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
DIFQZUMJGGXNSY-UHFFFAOYSA-N 1,3-dihydrothiadiazolo[3,4-a]benzimidazole-7-sulfonyl chloride Chemical compound C12=CC(S(=O)(=O)Cl)=CC=C2N=C2N1NSC2 DIFQZUMJGGXNSY-UHFFFAOYSA-N 0.000 claims 1
DSTMHLMDUYQOSG-UHFFFAOYSA-N 7-bromo-3-chloro-1,3-dihydrothiadiazolo[3,4-a]benzimidazole Chemical compound C1=C(Br)C=C2N3NSC(Cl)C3=NC2=C1 DSTMHLMDUYQOSG-UHFFFAOYSA-N 0.000 claims 1
JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 claims 1
102000004190 Enzymes Human genes 0.000 abstract description 8
108090000790 Enzymes Proteins 0.000 abstract description 8
230000015572 biosynthetic process Effects 0.000 abstract description 8
238000003786 synthesis reaction Methods 0.000 abstract description 7
206010061818 Disease progression Diseases 0.000 abstract description 2
230000005750 disease progression Effects 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
229910052757 nitrogen Inorganic materials 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000000243 solution Substances 0.000 description 18
239000013078 crystal Substances 0.000 description 17
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 15
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
238000000034 method Methods 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
239000003814 drug Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 9
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
229940079593 drug Drugs 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
239000002904 solvent Substances 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
MZZMLEBKMCHLIY-UHFFFAOYSA-N 3-chloro-1,3-dihydrothiadiazolo[3,4-a]benzimidazole Chemical compound C1=CC=C2N3NSC(Cl)C3=NC2=C1 MZZMLEBKMCHLIY-UHFFFAOYSA-N 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 7
241000283690 Bos taurus Species 0.000 description 6
101000984310 Bos taurus Carbonic anhydrase 2 Proteins 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 6
229910002092 carbon dioxide Inorganic materials 0.000 description 6
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 6
229940126214 compound 3 Drugs 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
ZWVYQZBCSXCUOO-UHFFFAOYSA-N 2,3,4,5,6-pentafluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ZWVYQZBCSXCUOO-UHFFFAOYSA-N 0.000 description 5
RWEWCXCNGMBHLA-UHFFFAOYSA-N 3-(dimethylamino)-1,3-dihydrothiadiazolo[3,4-a]benzimidazole-6-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C2N3NSC(N(C)C)C3=NC2=C1 RWEWCXCNGMBHLA-UHFFFAOYSA-N 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
239000001569 carbon dioxide Substances 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical class NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 4
208000010412 Glaucoma Diseases 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
229960000571 acetazolamide Drugs 0.000 description 4
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
229910021529 ammonia Inorganic materials 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
239000013058 crude material Substances 0.000 description 4
239000003446 ligand Substances 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
VWYTZNPMXYCBPK-UHFFFAOYSA-N 3-bromobenzene-1,2-diamine Chemical compound NC1=CC=CC(Br)=C1N VWYTZNPMXYCBPK-UHFFFAOYSA-N 0.000 description 3
102000005741 Metalloproteases Human genes 0.000 description 3
108010006035 Metalloproteases Proteins 0.000 description 3
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
150000008331 benzenesulfonamides Chemical class 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940125773 compound 10 Drugs 0.000 description 3
229940126543 compound 14 Drugs 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
229940126086 compound 21 Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003480 eluent Substances 0.000 description 3
238000000111 isothermal titration calorimetry Methods 0.000 description 3
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
229910000069 nitrogen hydride Inorganic materials 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000035790 physiological processes and functions Effects 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000004448 titration Methods 0.000 description 3
KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
MWDNZMWVENFVHT-UHFFFAOYSA-L (2-decoxy-2-oxoethyl)-[2-[2-[(2-decoxy-2-oxoethyl)-dimethylazaniumyl]ethylsulfanyl]ethyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCOC(=O)C[N+](C)(C)CCSCC[N+](C)(C)CC(=O)OCCCCCCCCCC MWDNZMWVENFVHT-UHFFFAOYSA-L 0.000 description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
XGJASKVXNPFPGD-UHFFFAOYSA-N 1h-thiadiazolo[3,4-a]benzimidazole-3-thione Chemical compound C1=CC=C2N=C3C(=S)SNN3C2=C1 XGJASKVXNPFPGD-UHFFFAOYSA-N 0.000 description 2
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
ZWPJFUYDBVTBQI-UHFFFAOYSA-N 5h-thieno[3,2-b]thiopyran Chemical class C1=CCSC2=C1SC=C2 ZWPJFUYDBVTBQI-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
108700012439 CA9 Proteins 0.000 description 2
102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
229960000722 brinzolamide Drugs 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
230000008859 change Effects 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125797 compound 12 Drugs 0.000 description 2
229940126208 compound 22 Drugs 0.000 description 2
WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 2
229960003314 deracoxib Drugs 0.000 description 2
229960005081 diclofenamide Drugs 0.000 description 2
GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
229960003933 dorzolamide Drugs 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 2
229950009881 indisulam Drugs 0.000 description 2
230000003993 interaction Effects 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
150000003577 thiophenes Chemical class 0.000 description 2
230000032258 transport Effects 0.000 description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
229960002004 valdecoxib Drugs 0.000 description 2
YVDZFDDZQSHIKO-UHFFFAOYSA-N (1-amino-5-bromobenzimidazol-2-yl)methanol Chemical compound BrC1=CC=C2N(N)C(CO)=NC2=C1 YVDZFDDZQSHIKO-UHFFFAOYSA-N 0.000 description 1
UXKYUWWDFGDPNI-UHFFFAOYSA-N (1-amino-6-bromobenzimidazol-2-yl)methanol Chemical compound C1=C(Br)C=C2N(N)C(CO)=NC2=C1 UXKYUWWDFGDPNI-UHFFFAOYSA-N 0.000 description 1
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 1
UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
SDYMYAFSQACTQP-UHFFFAOYSA-N 1,3-benzothiazole-2-sulfonamide Chemical class C1=CC=C2SC(S(=O)(=O)N)=NC2=C1 SDYMYAFSQACTQP-UHFFFAOYSA-N 0.000 description 1
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
HMDUADNDMXESSJ-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)benzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1C1=CC=NN1 HMDUADNDMXESSJ-UHFFFAOYSA-N 0.000 description 1
NXLCMRLZWXCRFO-UHFFFAOYSA-N 3-chloro-1,3-dihydrothiadiazolo[3,4-a]benzimidazole-7-sulfonamide Chemical compound C12=CC(S(=O)(=O)N)=CC=C2N=C2N1NSC2Cl NXLCMRLZWXCRFO-UHFFFAOYSA-N 0.000 description 1
SAPUDWLDIDIIJG-UHFFFAOYSA-N 3-chloro-1,3-dihydrothiadiazolo[3,4-a]benzimidazole-7-sulfonyl chloride Chemical compound C1=C(S(Cl)(=O)=O)C=C2N3NSC(Cl)C3=NC2=C1 SAPUDWLDIDIIJG-UHFFFAOYSA-N 0.000 description 1
IRPUFFXRAVWDDL-UHFFFAOYSA-N 3-methylsulfonyl-1,3-dihydrothiadiazolo[3,4-a]benzimidazole-7-sulfonyl chloride Chemical compound C1=C(S(Cl)(=O)=O)C=C2N3NSC(S(=O)(=O)C)C3=NC2=C1 IRPUFFXRAVWDDL-UHFFFAOYSA-N 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
102100033040 Carbonic anhydrase 12 Human genes 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000008445 altitude sickness Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
238000007707 calorimetry Methods 0.000 description 1
108010087312 carbonic anhydrase XII Proteins 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000037427 ion transport Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960004083 methazolamide Drugs 0.000 description 1
FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000029553 photosynthesis Effects 0.000 description 1
238000010672 photosynthesis Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
LBLZPOGZQOBQKC-UHFFFAOYSA-N thiadiazole-4-sulfonamide Chemical class NS(=O)(=O)C1=CSN=N1 LBLZPOGZQOBQKC-UHFFFAOYSA-N 0.000 description 1
150000004867 thiadiazoles Chemical class 0.000 description 1
DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical class S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
230000035922 thirst Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LT2006066A 2006-08-02 2006-08-02 Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti LT5504B (lt)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
LT2006066A LT5504B (lt)	2006-08-02	2006-08-02	Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti
AT07793796T ATE513836T1 (de)	2006-08-02	2007-08-01	Benzimidazoä1,2-cüä1,2,3üthiadiazol-7- sulfonsäureamide als carboanhydraseinhibitoren und zwischenprodukte zu deren herstellung
EP07793796A EP2054420B1 (de)	2006-08-02	2007-08-01	Benzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonsäureamide als carboanhydraseinhibitoren und zwischenprodukte zu deren herstellung
PCT/LT2007/000005 WO2008016288A1 (en)	2006-08-02	2007-08-01	Benzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
LT2006066A LT5504B (lt)	2006-08-02	2006-08-02	Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti

Publications (2)

Publication Number	Publication Date
LT2006066A LT2006066A (en)	2008-02-25
LT5504B true LT5504B (lt)	2008-06-25

Family

ID=38616554

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2006066A LT5504B (lt)	2006-08-02	2006-08-02	Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti

Country Status (4)

Country	Link
EP (1)	EP2054420B1 (de)
AT (1)	ATE513836T1 (de)
LT (1)	LT5504B (de)
WO (1)	WO2008016288A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201106548D0 (en) *	2011-04-18	2011-06-01	Evitraproteoma Ab	A method for determining ligand binding to a target protein using a thermal shift assahy
CN105362890A (zh) *	2015-12-18	2016-03-02	杜小卫	一种治疗女性肾虚症的中药药酒

Citations (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4668697A (en)	1983-10-31	1987-05-26	Merck & Co., Inc.	Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor
US4731368A (en)	1986-12-08	1988-03-15	Merck & Co., Inc.	Thienopyridine sulfonamides and their ophthalmological formulation
US4751231A (en)	1987-09-16	1988-06-14	Merck & Co., Inc.	Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US4788192A (en)	1983-06-20	1988-11-29	Merck & Co., Inc.	2-Sulfamoylbenzo(b)thiophene derivatives pharmaceutical compositions and use
US4798831A (en)	1987-09-16	1989-01-17	Merck & Co., Inc.	Substituted thieno[2,3-B]furan-2-sulfonamides as antiglaucoma agents
US4847289A (en)	1987-06-08	1989-07-11	Merck & Co., Inc.	Thiophene sulfonamide antiglaucoma agents
US4894390A (en)	1987-08-03	1990-01-16	Merck & Co., Inc.	Substituted thieno[2,3-b]thiophene-2-sulfonamides as antiglaucoma agents
US4929549A (en)	1989-02-08	1990-05-29	Merck & Co., Inc.	5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active carbonic anhydrase inhibitors
US4929637A (en)	1985-12-24	1990-05-29	Merck & Co., Inc.	Substituted thiophene-2-sulfonamide antiglaucoma agents
US4975447A (en)	1983-02-04	1990-12-04	University Of Iowa Research Foundation	6-hydroxyethoxy-2-benzothiazolesulfonamide and topical treatment compositions and method for glaucoma
US5059613A (en)	1990-03-19	1991-10-22	Research Corporation Technologies, Inc.	Topically active ocular benzothiazole sulfonamide carbonic anhydrase inhibitors
US5091409A (en)	1990-05-17	1992-02-25	Merck & Co., Inc.	4-alkylamino-6-(C3-5 -hydrocarbyl)thieno[2,3-B]thiopyran-2-sulfonamide-7,7-dioxides
US5093332A (en)	1990-10-01	1992-03-03	Merck & Co., Inc.	Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents
US5120757A (en)	1989-07-31	1992-06-09	Merck & Co., Inc.	Substituted aromatic sulfonamides as antiglaucoma agents
US5157129A (en)	1990-04-18	1992-10-20	Merck & Co., Inc.	Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
US5240923A (en)	1990-04-09	1993-08-31	Alcon Laboratories, Inc.	Sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en)	1990-04-09	1995-01-03	Alcon Laboratories, Inc.	Sulfonamides useful as carbonic anhydrase inhibitors
US5424448A (en)	1993-02-18	1995-06-13	Alcon Laboratories, Inc.	Preparation of carbonic anhydrase inhibitors
LT3368B (en)	1991-04-17	1995-08-25	Merck & Co Inc	Ophtalmic combinations of carbonic anhydrase inhibitors and b-blockers
US5464831A (en)	1994-09-09	1995-11-07	Alcon Laboratories, Inc.	Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US5510347A (en)	1994-09-09	1996-04-23	Alcon Laboratories, Inc.	Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US5519040A (en)	1994-04-29	1996-05-21	Allergan	Substituted thiazole sulfonamides as antiglaucoma agents
US5538966A (en)	1994-01-21	1996-07-23	Alcon Laboratories, Inc.	Carbonic anhydrase inhibitors
US5646142A (en)	1994-07-08	1997-07-08	Alcon Laboratories, Inc.	Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US6316443B1 (en)	1994-08-04	2001-11-13	Merck & Co., Inc.	Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
WO2004048544A2 (en)	2002-11-26	2004-06-10	Bayer Healthcare	Ca ix-specific inhibitors
WO2005107470A2 (en)	2004-04-29	2005-11-17	University Of Florida Research Foundation, Inc.	Use of carbonic anhydrase inhibitors for insect control and malaria treatment
US7030250B2 (en)	2000-09-04	2006-04-18	Ragatives, S.L.	Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5235059A (en) *	1991-10-15	1993-08-10	Merck & Co., Inc.	Tricyclic thienothiopyran carbonic anhydrase inhibitors
US5681834A (en) *	1995-12-04	1997-10-28	Alcon Laboratories, Inc.	Heterocyclic sulfonamides
JP2005501083A (ja) *	2001-08-10	2005-01-13	ファルマシア・コーポレーション	炭酸脱水酵素阻害剤

2006
- 2006-08-02 LT LT2006066A patent/LT5504B/lt not_active IP Right Cessation
2007
- 2007-08-01 EP EP07793796A patent/EP2054420B1/de not_active Not-in-force
- 2007-08-01 WO PCT/LT2007/000005 patent/WO2008016288A1/en not_active Ceased
- 2007-08-01 AT AT07793796T patent/ATE513836T1/de not_active IP Right Cessation

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4975447A (en)	1983-02-04	1990-12-04	University Of Iowa Research Foundation	6-hydroxyethoxy-2-benzothiazolesulfonamide and topical treatment compositions and method for glaucoma
US4788192A (en)	1983-06-20	1988-11-29	Merck & Co., Inc.	2-Sulfamoylbenzo(b)thiophene derivatives pharmaceutical compositions and use
US4668697A (en)	1983-10-31	1987-05-26	Merck & Co., Inc.	Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor
US4929637A (en)	1985-12-24	1990-05-29	Merck & Co., Inc.	Substituted thiophene-2-sulfonamide antiglaucoma agents
US4731368A (en)	1986-12-08	1988-03-15	Merck & Co., Inc.	Thienopyridine sulfonamides and their ophthalmological formulation
US4847289A (en)	1987-06-08	1989-07-11	Merck & Co., Inc.	Thiophene sulfonamide antiglaucoma agents
US4894390A (en)	1987-08-03	1990-01-16	Merck & Co., Inc.	Substituted thieno[2,3-b]thiophene-2-sulfonamides as antiglaucoma agents
US4751231A (en)	1987-09-16	1988-06-14	Merck & Co., Inc.	Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US4798831A (en)	1987-09-16	1989-01-17	Merck & Co., Inc.	Substituted thieno[2,3-B]furan-2-sulfonamides as antiglaucoma agents
US4929549A (en)	1989-02-08	1990-05-29	Merck & Co., Inc.	5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active carbonic anhydrase inhibitors
US5120757A (en)	1989-07-31	1992-06-09	Merck & Co., Inc.	Substituted aromatic sulfonamides as antiglaucoma agents
US5059613A (en)	1990-03-19	1991-10-22	Research Corporation Technologies, Inc.	Topically active ocular benzothiazole sulfonamide carbonic anhydrase inhibitors
US5378703A (en)	1990-04-09	1995-01-03	Alcon Laboratories, Inc.	Sulfonamides useful as carbonic anhydrase inhibitors
US5240923A (en)	1990-04-09	1993-08-31	Alcon Laboratories, Inc.	Sulfonamides useful as carbonic anhydrase inhibitors
US5157129A (en)	1990-04-18	1992-10-20	Merck & Co., Inc.	Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
US5091409A (en)	1990-05-17	1992-02-25	Merck & Co., Inc.	4-alkylamino-6-(C3-5 -hydrocarbyl)thieno[2,3-B]thiopyran-2-sulfonamide-7,7-dioxides
US5093332A (en)	1990-10-01	1992-03-03	Merck & Co., Inc.	Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents
US6248735B1 (en)	1991-04-17	2001-06-19	Merck & Co., Inc.	Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
LT3368B (en)	1991-04-17	1995-08-25	Merck & Co Inc	Ophtalmic combinations of carbonic anhydrase inhibitors and b-blockers
US5424448A (en)	1993-02-18	1995-06-13	Alcon Laboratories, Inc.	Preparation of carbonic anhydrase inhibitors
US5538966A (en)	1994-01-21	1996-07-23	Alcon Laboratories, Inc.	Carbonic anhydrase inhibitors
US5519040A (en)	1994-04-29	1996-05-21	Allergan	Substituted thiazole sulfonamides as antiglaucoma agents
US5646142A (en)	1994-07-08	1997-07-08	Alcon Laboratories, Inc.	Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US6316443B1 (en)	1994-08-04	2001-11-13	Merck & Co., Inc.	Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5464831A (en)	1994-09-09	1995-11-07	Alcon Laboratories, Inc.	Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US5510347A (en)	1994-09-09	1996-04-23	Alcon Laboratories, Inc.	Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US7030250B2 (en)	2000-09-04	2006-04-18	Ragatives, S.L.	Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates
WO2004048544A2 (en)	2002-11-26	2004-06-10	Bayer Healthcare	Ca ix-specific inhibitors
US20040146955A1 (en)	2002-11-26	2004-07-29	Claudiu Supuran	CA IX-specific inhibitors
WO2005107470A2 (en)	2004-04-29	2005-11-17	University Of Florida Research Foundation, Inc.	Use of carbonic anhydrase inhibitors for insect control and malaria treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUPURAN CT, SCOZZAFAVA A.: "Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?", EUR J MED CHEM., 2000, pages 867 - 874

Also Published As

Publication number	Publication date
WO2008016288A1 (en)	2008-02-07
EP2054420A1 (de)	2009-05-06
LT2006066A (en)	2008-02-25
ATE513836T1 (de)	2011-07-15
EP2054420B1 (de)	2011-06-22

Legal Events

Date	Code	Title	Description
2015-03-25	MM9A	Lapsed patents	Effective date: 20140802

Publication	Publication Date	Title
EP2183254B1 (de)	2017-06-21	Inhibitoren der proteintyrosinkinaseaktivität
RU2126798C1 (ru)	1999-02-27	Производное сахарина или его фармацевтически приемлемая соль, фармацевтическая композиция для ингибирования протеолитических ферментов при лечении дегенеративных заболеваний
US8383839B2 (en)	2013-02-26	Heterocyclidene acetamide derivative
US9585892B2 (en)	2017-03-07	Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Bozdag et al.	2017	Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity
TR201901886T4 (tr)	2019-03-21	DNA-PK inhibitörleri.
Chegaev et al.	2014	Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents
CA2676020A1 (en)	2008-07-31	Heterocyclidene-n-(aryl) acetamide derivative
JP2005516023A (ja)	2005-06-02	プロテインチロシンキナーゼ阻害剤としてのチエノピリミジン化合物
ES2803028T3 (es)	2021-01-22	Partículas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-formil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-naftiridin-1(2h)-carboxamida
JP2024501118A (ja)	2024-01-11	Ｋｒａｓ修飾のための方法および組成物
CN107721933A (zh)	2018-02-23	磺酰苯并咪唑醇化合物及其制备方法和应用
CN110078663B (zh)	2022-07-29	一种母核为四氢喹啉的磺酰胺类化合物及其制备方法和应用
WO2010038803A1 (ja)	2010-04-08	２－インドールアクリルアミド類縁体
CA2784749A1 (en)	2011-06-23	Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
LT5504B (lt)	2008-06-25	Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti
HU222274B1 (hu)	2003-05-28	Leukotrién antagonista hatású diaril-5,6-(kondenzált heterociklusos savak), eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
CN102807574B (zh)	2015-09-02	新型吡啶并硫氮七元环衍生物作为抗肿瘤药物、及其制备方法和应用
CN101898985B (zh)	2014-05-28	Bcl-2蛋白的N-取代苯磺酰基-取代苯甲酰胺类小分子抑制剂及其应用
CN101228131B (zh)	2013-01-09	新的杂环亚基乙酰胺衍生物
WO2014066506A2 (en)	2014-05-01	Compositions and methods for jamm protein inhibition
CN103360390B (zh)	2015-06-17	中氮茚甲酰甲基对甲磺酰胺苯乙胺衍生物及其医药用途
CN104496926B (zh)	2016-06-01	一类含二烯四氮唑结构的化合物、其制备方法和用途
CN104496925B (zh)	2016-04-06	二烯四氮唑类化合物、其制备方法和用途
CN104496923B (zh)	2016-04-06	硝基苯二烯四氮唑类化合物、其制备方法和用途